<DOC>
	<DOCNO>NCT01675024</DOCNO>
	<brief_summary>This study characterize Pharmacokinetics ( PK ) unconjugated total Rotigotine single multiple dos Rotigotine transdermal patch , also investigate safety tolerability Rotigotine transdermal patch healthy Chinese subject .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Safety , Tolerability Rotigotine Transdermal Patch Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>Chinese subject Healthy volunteer normal body weight , female subject willing use double contraceptive barrier method oral hormonal contraceptive entire study Previously participate Rotigotine study participate another clinical study investigational drug History drug alcohol abuse within last 2 year Suicide attempt suicidal ideation past 6 month Transient ischemic attack stroke within last 12 month Current condition epilepsy / seizures History significant skin hypersensitivity adhesives transdermal product recently unsolved contact dermatitis History present condition atopic eczematous dermatitis , psoriasis / active skin disease Female subject pregnant lactating Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's wellbeing ability participate study Subject QTcB ( QT interval correct heart rate accord Bazett 's formula ) interval ≥ 450 ms female ≥ 430 ms male Subject relevant hepatic dysfunction ( total bilirubin &gt; 2 mg / dL alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] great 2 time upper limit normal reference range ) Subject test positive human immunodeficiency virus antibody ( HIV ) 1 / 2Ab , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) Subject positive urine drug screen / alcohol breath test Day 1 Subject make blood donation comparable blood loss ( &gt; 400 mL ) Subject smoke do within 6 month prior Eligibility Assessment ( EA ) Subject clinically relevant allergy Subject currently take medication Female subject currently take oral hormonal contraceptive Subject symptomatic orthostatic hypotension Subject pulse rate rest le 45 beat per minute ( bpm ) 100 bpm Subject systolic blood pressure ( SBP ) low 100 mmHg high 140 mmHg diastolic blood pressure ( DBP ) high 90 mmHg Subject current history clinically relevant motor disturbance , impairment memory , sleep disturbance neurodegenerative disease Subject consume 3 cup ( 450 ml ) caffeinated beverage per day Subject 's abdomen thickly cover hair result difficulty find appropriate patch application site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Neupro , Pharmacokinetics , healthy Chinese subject</keyword>
</DOC>